Immunotherapy with liver-directed treatment before surgery for high-risk liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new approach: giving two immunotherapy drugs (sintilimab and ipilimumab) along with treatments that block blood flow to the tumor (TACE or ablation) before surgery for liver cancer that is at high risk of coming back. The goal is to see if this combination can shrink the tumor and reduce the chance of recurrence after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and have been diagnosed with liver cancer that can be removed with surgery (but has a higher chance of coming back).
- You have not had any previous treatment for liver cancer (like surgery, chemo, or radiation).
- Your liver function is good (doctors call this Child-Pugh class A), and you are otherwise healthy enough for surgery and study treatments.
- You do not have significant spread of cancer to major blood vessels or to other organs, and your cancer has not ruptured or caused bleeding.
- You do not have active hepatitis B or C, or if you do, it must be well controlled with medication during the study.
- You have not had autoimmune diseases, organ transplants, or recent serious heart or bleeding conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This study tests whether giving a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks tumor growth)—before surgery can improve outcomes for people with early-stage liver cancer (a single tumor 2-5 cm) when the surgery is likely to have a narrow margin. You would receive the drugs for a few weeks before your scheduled surgery, and then have the surgery as planned. This approach may help reduce the chance of the cancer coming back.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.